Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Completed 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 2Lymphoid 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1

Conditions

Chordoma 1

Interventions

Doxorubicin 25Radiotherapy 16apatinib 15Cyclophosphamide 15Ifosfamide 13anlotinib 12camrelizumab 10Temozolomide 9Imatinib Mesylate 9Vincristine 8Surgical Procedures, Operative 7Neoadjuvant Therapy 7Methotrexate 7Drug Therapy 7Dactinomycin 5Blood Specimen Collection 5fludarabine phosphate 4Paclitaxel 4Immune Checkpoint Inhibitors 4Etoposide 4Docetaxel 4Carboplatin 4toripalimab 3pembrolizumab 3Trabectedin 3Topotecan 3Surveys and Questionnaires 3Radiation Dose Hypofractionation 3Nivolumab 3Melphalan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Panobinostat × Sarcoma × Clear all
NCT01175109 2012-12-27

Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma

University of Virginia

Phase 1 Unknown
36 enrolled
Sarcoma

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡